GSK Wants USPTO Appeals Board Ruling Overturned

Law360, New York (September 16, 2008, 12:00 AM EDT) -- The U.S. Board of Patent Appeals and Interferences has erroneously invalidated claims for several inhaler patents in favor of Novartis Corp., according to a complaint filed by Glaxo Group Ltd. and SmithKline Beecham Corp.

GSK lodged the suit on Friday in the U.S. District Court for the District of Columbia, asking the court to overturn decisions made by the U.S. Patent and Trademark Office's appeals and interferences board during a July interference proceeding between the pharmaceutical giants.

According to the complaint, the interference board initiated the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.